Skip to main content

Table 1 Baseline characteristics of patients with ypT0-3N0 rectal cancer

From: Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery

  

Before matching

After matching

Overall n = 339 (%)

No AC n = 87 (%)

AC n = 252 (%)

p-value

No AC n = 87 (%)

AC n = 87 (%)

p-value

Median age (range), years

59.6 (27.2–85.7)

65.9 (36.0–85.7)

58.3 (27.2–84.6)

<0.001

65.9 (36.0–85.7)

63.7 (39.1–84.6)

0.251

Sex

   

0.752

  

0.602

 Male

246 (72.6)

62 (71.3)

184 (73.0)

 

62 (71.3)

59 (67.8)

 

 Female

93 (27.4)

25 (28.7)

68 (27.0)

 

25 (28.7)

28 (32.2)

 

Distance from AV (cm)

      

0.342

 ≥ 10.0

35 (10.3)

8 (9.2)

27 (10.7)

 

8 (9.2)

9 (10.3)

 

 5.0–9.9

140 (41.3)

33 (37.9)

107 (42.5)

 

33 (37.9)

40 (46.0)

 

 < 5.0

164 (48.4)

46 (52.9)

118 (46.8)

 

46 (52.9)

38 (43.7)

 

Differentiation

   

0.176

  

0.300

 Well

70 (20.6)

17 (19.5)

53 (21.0)

 

17 (19.5)

20 (23.0)

 

 Moderate

248 (73.2)

61 (70.1)

187 (74.2)

 

61 (70.1)

62 (71.3)

 

 Poor, mucinous

21 (6.2)

9 (10.3)

12 (4.8)

 

9 (10.3)

5 (5.7)

 

Pretreatment CEA (ng/mL)

   

0.621

  

0.413

 < 5

214 (63.1)

53 (60.9)

161 (63.9)

 

53 (60.9)

58 (66.7)

 

 ≥ 5

125 (36.9)

34 (39.1)

91 (36.1)

 

34 (39.1)

29 (33.3)

 

Surgical procedure

   

0.573

  

0.350

 LAR

298 (87.9)

75 (86.2)

232 (88.5)

 

75 (86.2)

79 (90.8)

 

 APR

41 (12.1)

12 (13.8)

29 (11.5)

 

12 (13.8)

8 (9.2)

 

Stage

   

<0.001

  

0.383

 ypT0

90 (26.5)

40 (46.0)

50 (19.8)

 

40 (46.0)

37 (42.5)

 

 ypT1

19 (5.6)

6 (6.9)

13 (5.2)

 

6 (6.9)

4 (4.6)

 

 ypT2

96 (28.3)

25 (28.7)

71 (28.2)

 

25 (28.7)

26 (29.9)

 

 ypT3

134 (39.5)

16 (18.4)

118 (46.8)

 

16 (18.4)

20 (23.0)

 

LN dissected

   

0.146

  

0.538

 < 12

145 (42.8)

43 (49.4)

102 (40.5)

 

43 (49.4)

39 (44.8)

 

 ≥ 12

194 (57.2)

44 (50.6)

150 (59.5)

 

44 (50.6)

48 (55.2)

 

LVI/PNI

   

0.812

  

0.657

 Negative

278 (82.0)

71 (81.6)

207 (82.1)

 

71 (81.6)

80 (92.0)

 

 Positive

15 (4.4)

3 (3.4)

12 (4.8)

 

3 (3.5)

2 (2.3)

 

 NA

46 (13.6)

13 (14.9)

33 (13.1)

 

13 (14.9)

5 (5.8)

 

Margin

   

0.677

  

1.000

 Negative

329 (97.1)

85 (97.7)

244 (96.8)

 

85 (97.7)

85 (97.7)

 

 Positive

10 (2.9)

2 (2.3)

8 (3.2)

 

2 (2.3)

2 (2.3)

 

Mandard regression grade

   

<0.001

  

0.926

 Grade 1

90 (26.5)

40 (46.0)

50 (19.8)

 

40 (46.0)

37 (42.5)

 

 Grade 2

90 (26.5)

17 (19.5)

73 (29.0)

 

17 (19.5)

22 (25.3)

 

 Grade 3

78 (23.0)

11 (12.6)

67 (26.6)

 

11 (12.6)

15 (17.2)

 

 Grade 4

36 (10.6)

6 (6.9)

30 (11.9)

 

6 (6.9)

8 (9.2)

 

 NA

45 (13.3)

13 (14.9)

32 (12.7)

 

13 (14.9)

5 (5.8)

 
  1. AC adjuvant chemotherapy, AV anal verge, CEA carcinoembryonic antigen, LAR lower anterior resection, APR abdomino-perineal resection, LN lymph node, LVI lymphovascular invasion, PNI perineural invasion, NA not assessed
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us